Richtlijn Niercelcarcinoom
Richtlijn Niercelcarcinoom
Richtlijn Niercelcarcinoom
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
de Mulder, P. H., Oosterhof, G., Bouffioux, C., van Oosterom, A. T., Vermeylen, K., and<br />
Sylvester, R. EORTC (30885) randomised phase III study with recombinant interferon alpha<br />
and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma.<br />
The EORTC Genitourinary Group. Br.J.Cancer 1995, 71: 371-375<br />
Escudier, B., Chevreau, C., Lasset, C., Douillard, J. Y., Ravaud, A., Fabbro, M., Caty, A.,<br />
Rossi, J. F., Viens, P., Bergerat, J. P., Savary, J., and Negrier, S. Cytokines in metastatic<br />
renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first<br />
treatment? Groupe Francais d'Immunotherape. J.Clin.Oncol. 1999, 17: 2039-2043<br />
Figlin, R. A., Thompson, J. A., Bukowski, R. M., Vogelzang, N. J., Novick, A. C., Lange, P.,<br />
Steinberg, G. D., and Belldegrun, A. S. Multicenter, randomized, phase III trial of CD8(+)<br />
tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic<br />
renal cell carcinoma. J.Clin.Oncol. 1999, 17: 2521-2529<br />
Fossa, S. D., Mickisch, G. H., de Mulder, P. H., Horenblas, S., van Oosterom, A. T., van<br />
Poppel, H., Fey, M., Croles, J. J., de Prijck, L., and van Glabbeke, M. Interferon-alpha-2a<br />
with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal<br />
cell carcinoma. Cancer 2004, 101: 533-540<br />
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., and Louie, A. C.<br />
Results of treatment of 255 patients with metastatic renal cell carcinoma who received highdose<br />
recombinant interleukin-2 therapy. J.Clin.Oncol., 13: 688-696, 1995<br />
Hernberg, M., Pyrhonen, S., and Muhonen, T. Regimens with or without interferon-alpha as<br />
treatment for metastatic melanoma and renal cell carcinoma. J Immunother. 1999<br />
Mar;22(2):145-54.<br />
Lee, D. S., White, D. E., Hurst, R., Rosenberg, S. A., and Yang, J. C. Patterns of relapse and<br />
response to retreatment in patients with metastatic melanoma or renal cell carcinoma who<br />
responded to interleukin-2-based immunotherapy. Cancer J Sci.Am 1998, 4: 86-93<br />
McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F.,<br />
Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., Tretter, C. P., Urba, W. J.,<br />
Smith, J. W., Margolin, K. A., Mier, J. W., Gollob, J. A., Dutcher, J. P., and Atkins, M. B.<br />
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and<br />
interferon in patients with metastatic renal cell carcinoma. J.Clin.Oncol. 2005, 23: 133-141<br />
Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer,<br />
P., Wilding, G., Fairclough, D. L., Cella, D., and Mazumdar, M. Phase III trial of interferon<br />
alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J<br />
Clin.Oncol. 2000, 18: 2972-2980<br />
Negrier, S., Escudier, B., Lasset, C., Douillard, J. Y., Savary, J., Chevreau, C., Ravaud, A.,<br />
Mercatello, A., Peny, J., Mousseau, M., Philip, T., and Tursz, T. Recombinant human<br />
interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell<br />
carcinoma. Groupe Francais d'Immunotherapie. N.Engl.J.Med. 1998, 338: 1272-1278<br />
Neidhart, J. A., Anderson, S. A., Harris, J. E., Rinehart, J. J., Laszlo, J., Dexeus, F. H.,<br />
Einhorn, L. H., Trump, D. L., Benedetto, P. W., Tuttle, R. L., and . Vinblastine fails to improve<br />
response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary<br />
metastases. J.Clin.Oncol. 1991 9: 832-836<br />
Palmer, P. A., Vinke, J., Evers, P., Pourreau, C., Oskam, R., Roest, G., Vlems, F., Becker,<br />
L., Loriaux, E., and Franks, C. R. Continuous infusion of recombinant interleukin-2 with or<br />
without autologous lymphokine activated killer cells for the treatment of advanced renal cell<br />
carcinoma. Eur .J.Cancer 1992, 28A: 1038-1044<br />
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber,<br />
D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., and . Prospective randomized<br />
trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for<br />
the treatment of patients with advanced cancer. J. Natl.Cancer Inst. 1993, 85: 622-632.<br />
Sagaster, P., Micksche, M., Flamm, J., and Ludwig, H. Randomised study using IFN-alpha<br />
versus IFN-alpha plus coumarin and cimetidine for treatment of advanced renal cell cancer.<br />
Ann.Oncol. 1995, 6: 999-1003<br />
91
Change language